Zambezi Rts 15May (ZRLR) News

Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024

Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to...

Form 8-K - Current report

Xeris Biopharma Announces CEO Succession Plan

John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid...

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024

In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower...

Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)

XeriSol™ formulation enabled predictable bioavailability and sustained levels of levothyroxine in a once-weekly subcutaneous presentation...

Xeris to Participate in the Jefferies Global Healthcare Conference

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing...

Form 8-K - Current report

Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events

Q1 2024 Total Revenue of $40.6M – up 22% over Q1 2023 Tightening full-year 2024 total revenue guidance to $175M-$200M Ended Q1 with $87.4M in...

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

For development and commercialization of a new and unique formulation of liquid stable glucagon for use in a bi-hormonal pump and pump systems...

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024

Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to...

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and...

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing...